
News|Articles|May 1, 2006
Pipeline Preview (May 2006)
Approvable designations
Advertisement
Approvable designations
• Sitaxsentan (Thelin, Encysive Pharmaceuticals) for the treatment of pulmonary arterial hypertension
Fast-track designations
Priority review
• Infliximab (Remicade, Centocor) for pediatric Crohn's disease
Orphan drug designations
• Cell-permeable peptide (AM-111, Auris Medical) for acute sensorineural hearing loss
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows
2
Real-World Usage of Biologics in Psoriatic Arthritis
3
Medicare beneficiaries are paying more for price-negotiated drugs, survey finds
4
Researchers discover new pathway to fight liver inflammation
5





















